Hashimoto's Thyroiditis Negatively Influences Intracytoplasmic Sperm Injection Outcome in Euthyroid Women on T4 Substitution Therapy: A Retrospective Study.
Tünde Herman, Péter Török, Antonio Simone Laganà, Vito Chiantera, Renato Venezia, Attila Jakab
{"title":"Hashimoto's Thyroiditis Negatively Influences Intracytoplasmic Sperm Injection Outcome in Euthyroid Women on T4 Substitution Therapy: A Retrospective Study.","authors":"Tünde Herman, Péter Török, Antonio Simone Laganà, Vito Chiantera, Renato Venezia, Attila Jakab","doi":"10.1159/000537836","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The objective of this study was to analyze the impact of thyroid autoimmunity (TAI) on reproductive outcome parameters of intracytoplasmic sperm injection (ICSI) cycles as compared to TAI-negative ICSI cycles.</p><p><strong>Design: </strong>In this single in vitro fertilization (IVF) center retrospective study, 86 infertile women with elevated thyroid peroxidase or TGAb levels, but euthyroid after thyroxine replacement (study group), were compared to 69 female patients with no thyroid abnormalities (controls). Following ICSI treatment fertilization rate (FR), clinical pregnancy rate (CPR), miscarriage rate (MR), and live birth rate (LBR) were analyzed.</p><p><strong>Materials, setting, methods: </strong>All subjects with various infertility factors were treated with ICSI in university-based IVF center. Patients in the study group received thyroxine replacement and were euthyroid at IVF treatment. Before the IVF cycles, endocrinological parameters were uniformly assessed: thyroid function and antibodies, reproductive hormones (anti-Müllerian hormone [AMH], follicular stimulating hormone [FSH], luteinizing hormone, E2, PRL, testosterone, DHEAS, 17-OHP, AD) and OGTT (0-60-120 min glucose and insulin). Following descriptive comparison of laboratory parameters, age-adjusted analyses of FR, CPR, MR, and LBR were performed.</p><p><strong>Results: </strong>TAI-positive women were older (mean age 35.31 ± 4.95 vs. 32.15 ± 4.87 years; p = 0.002), had higher FSH (8.4 ± 3.4 vs. 7.4 ± 2.32 U/L; p = 0.024), higher E2 (53.94 ± 47.61 vs. 42.93 ± 18.92 pg/mL; p = 0.025) levels, while AMH (2.88 ± 2.62 vs. 3.61 ± 1.69 ng/mL; p = 0.0002) was lower. There were no differences in TSH levels (1.64 ± 0.96 vs. 1.66 ± 0.65 µIU/mL; p = 0.652) between the two groups. FT3 (2.63 ± 0.58 vs. 2.98 ± 0.55 pg/mL; p = 0.002) was lower and FT4 (1.3 ± 0.29 vs. 1.13 ± 0.21 ng/dL; p = 0.0002) was higher in the TAI-positive group, reflecting clinically irrelevant differences. Egg cell counts (6 ± 3.8 vs. 7.5 ± 3.95; p = 0.015) were lower in TAI and remained so following age adjustment. Although the overall ICSI FR did not differ (62.9% vs. 69.1%, p = 0.12), it was lower for patients under 35 with TAI showing decreasing differences in line with age. The CPR (36.04% vs. 69.56%; p < 0.001) and LBR (23.25% vs. 60.86%; p < 0.001) were lower, the MR (35.48% vs. 12.5%; p = 0.024) was higher in the TAI group, and these differences remained after age adjustment.</p><p><strong>Limitations: </strong>Since the higher age of the study group may interfere with the effect of TAI, age adjustment calculations were necessary to perform to eliminate this confounding factor.</p><p><strong>Conclusion: </strong>Despite optimal thyroid supplementation in clinical or subclinical hypothyroidism, the presence of TAI negatively influences CPR and is connected to a higher MR, thus resulting in a lower LBR after ICSI. Decreased FR with ICSI in TAI patients may also contribute to poorer outcomes, especially in younger women.</p>","PeriodicalId":12952,"journal":{"name":"Gynecologic and Obstetric Investigation","volume":" ","pages":"150-158"},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic and Obstetric Investigation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000537836","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/17 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The objective of this study was to analyze the impact of thyroid autoimmunity (TAI) on reproductive outcome parameters of intracytoplasmic sperm injection (ICSI) cycles as compared to TAI-negative ICSI cycles.
Design: In this single in vitro fertilization (IVF) center retrospective study, 86 infertile women with elevated thyroid peroxidase or TGAb levels, but euthyroid after thyroxine replacement (study group), were compared to 69 female patients with no thyroid abnormalities (controls). Following ICSI treatment fertilization rate (FR), clinical pregnancy rate (CPR), miscarriage rate (MR), and live birth rate (LBR) were analyzed.
Materials, setting, methods: All subjects with various infertility factors were treated with ICSI in university-based IVF center. Patients in the study group received thyroxine replacement and were euthyroid at IVF treatment. Before the IVF cycles, endocrinological parameters were uniformly assessed: thyroid function and antibodies, reproductive hormones (anti-Müllerian hormone [AMH], follicular stimulating hormone [FSH], luteinizing hormone, E2, PRL, testosterone, DHEAS, 17-OHP, AD) and OGTT (0-60-120 min glucose and insulin). Following descriptive comparison of laboratory parameters, age-adjusted analyses of FR, CPR, MR, and LBR were performed.
Results: TAI-positive women were older (mean age 35.31 ± 4.95 vs. 32.15 ± 4.87 years; p = 0.002), had higher FSH (8.4 ± 3.4 vs. 7.4 ± 2.32 U/L; p = 0.024), higher E2 (53.94 ± 47.61 vs. 42.93 ± 18.92 pg/mL; p = 0.025) levels, while AMH (2.88 ± 2.62 vs. 3.61 ± 1.69 ng/mL; p = 0.0002) was lower. There were no differences in TSH levels (1.64 ± 0.96 vs. 1.66 ± 0.65 µIU/mL; p = 0.652) between the two groups. FT3 (2.63 ± 0.58 vs. 2.98 ± 0.55 pg/mL; p = 0.002) was lower and FT4 (1.3 ± 0.29 vs. 1.13 ± 0.21 ng/dL; p = 0.0002) was higher in the TAI-positive group, reflecting clinically irrelevant differences. Egg cell counts (6 ± 3.8 vs. 7.5 ± 3.95; p = 0.015) were lower in TAI and remained so following age adjustment. Although the overall ICSI FR did not differ (62.9% vs. 69.1%, p = 0.12), it was lower for patients under 35 with TAI showing decreasing differences in line with age. The CPR (36.04% vs. 69.56%; p < 0.001) and LBR (23.25% vs. 60.86%; p < 0.001) were lower, the MR (35.48% vs. 12.5%; p = 0.024) was higher in the TAI group, and these differences remained after age adjustment.
Limitations: Since the higher age of the study group may interfere with the effect of TAI, age adjustment calculations were necessary to perform to eliminate this confounding factor.
Conclusion: Despite optimal thyroid supplementation in clinical or subclinical hypothyroidism, the presence of TAI negatively influences CPR and is connected to a higher MR, thus resulting in a lower LBR after ICSI. Decreased FR with ICSI in TAI patients may also contribute to poorer outcomes, especially in younger women.
目的与TAI阴性的ICSI周期相比,分析甲状腺自身免疫(TAI)对ICSI周期生殖结果参数的影响:在这项单一试管婴儿中心的回顾性研究中,86名TPOAb或TGAb水平升高但甲状腺素替代后甲状腺功能正常的不孕女性(研究组)与69名无甲状腺异常的女性患者(对照组)进行了比较。对ICSI治疗后的受精率(FR)、临床妊娠率(CPR)、流产率(MR)和活产率(LBR)进行分析:所有具有各种不孕症因素的受试者均在大学试管婴儿中心接受了卵胞浆内单精子显微注射治疗。研究组中的患者在接受体外受精治疗时接受了甲状腺素替代治疗,并保持健康。在试管婴儿周期前,对内分泌参数进行了统一评估:甲状腺功能和抗体、生殖激素(AMH、FSH、LH、E2、PRL、睾酮、DHEAS、17-OHP、AD)和 OGTT(0-60-120 分钟葡萄糖和胰岛素)。在对实验室参数进行描述性比较后,对 FR、CPR、MR 和 LBR 进行了年龄调整分析:结果:TAI 阳性女性年龄更大(平均年龄为 35.31±4.95 岁 vs. 32.15±4.87 岁;P=0.002),FSH 更高(8.4±3.4 vs. 7.4±2.32 U/L;P=0.024),E2(53.94±47.61 vs. 42.93±18.92 pg/ml;p=0.025)水平较高,而AMH(2.88±2.62 vs. 3.61±1.69 ng/ml;p=0.0002)较低。两组的促甲状腺激素水平(1.64±0.96 vs. 1.66±0.65 uIU/ml;P=0.652)无差异。TAI阳性组的FT3(2.63±0.58 vs. 2.98±0.55 pg/ml;p=0.002)较低,FT4(1.3±0.29 vs. 1.13±0.21 ng/dl;p=0.0002)较高,反映了临床上无意义的差异。TAI阳性组的卵细胞计数(6±3.8 vs. 7.5±3.95;p=0.015)较低,经年龄调整后仍然如此。尽管ICSI FR的总体水平没有差异(62.9% vs. 69.1%,p=0.12),但35岁以下患者的ICSI FR较低,而TAI的差异随着年龄的增长而减小。CPR(36.04% vs. 69.56%;P=0.12):由于研究组的年龄较高,可能会干扰TAI的效果,因此有必要进行年龄调整计算,以消除这一干扰因素:结论:尽管临床或亚临床甲状腺功能减退症患者接受了最佳的甲状腺补充治疗,但TAI的存在会对临床妊娠率产生负面影响,并与较高的流产率有关,从而导致ICSI后的活产率降低。TAI患者ICSI受精率的降低也可能导致较差的结果,尤其是对年轻女性而言。
期刊介绍:
This journal covers the most active and promising areas of current research in gynecology and obstetrics. Invited, well-referenced reviews by noted experts keep readers in touch with the general framework and direction of international study. Original papers report selected experimental and clinical investigations in all fields related to gynecology, obstetrics and reproduction. Short communications are published to allow immediate discussion of new data. The international and interdisciplinary character of this periodical provides an avenue to less accessible sources and to worldwide research for investigators and practitioners.